See more : China Glass Holdings Limited (3300.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Pharmaceuticals Inc. (MIST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ABIVAX Société Anonyme (0RA9.L) Income Statement Analysis – Financial Results
- Fuse Cobalt Inc. (FUSE.V) Income Statement Analysis – Financial Results
- China Merchants Port Holdings Company Limited (CMHHY) Income Statement Analysis – Financial Results
- FRP Advisory Group plc (FRP.L) Income Statement Analysis – Financial Results
- MEMSCAP, S.A. (MEMS.PA) Income Statement Analysis – Financial Results
Milestone Pharmaceuticals Inc. (MIST)
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 480.00K | 0.00 | 376.00K | 236.00K | 10.00K | 8.00K |
| Gross Profit | 1.00M | 4.52M | 15.00M | -376.00K | -236.00K | -10.00K | -8.00K |
| Gross Profit Ratio | 100.00% | 90.40% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.05M | 39.83M | 38.67M | 34.49M | 41.99M | 16.85M | 5.64M |
| General & Administrative | 15.93M | 15.72M | 12.40M | 10.29M | 7.00M | 3.05M | 1.50M |
| Selling & Marketing | 15.11M | 9.10M | 7.00M | 5.94M | 8.89M | 3.92M | 1.13M |
| SG&A | 31.05M | 24.81M | 19.40M | 16.22M | 15.90M | 6.97M | 2.63M |
| Other Expenses | 0.00 | 0.00 | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Cost & Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Interest Income | 3.97M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Interest Expense | 2.55M | 0.00 | 0.00 | 726.00K | 2.60M | 0.00 | 0.00 |
| Depreciation & Amortization | 92.00K | 480.00K | 362.00K | 376.00K | 236.00K | 10.00K | 8.00K |
| EBITDA | -56.85M | -58.36M | -42.98M | -50.71M | -57.88M | -23.36M | -8.26M |
| EBITDA Ratio | -5,684.50% | -1,192.84% | -286.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.10M | -59.64M | -43.07M | -50.71M | -57.88M | -23.82M | -8.27M |
| Operating Income Ratio | -6,109.80% | -1,192.84% | -287.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.41M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Income Before Tax | -59.69M | -58.39M | -42.85M | -49.98M | -55.29M | -23.11M | -8.08M |
| Income Before Tax Ratio | -5,968.50% | -1,167.76% | -285.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.25M | -220.00K | -17.00K | -56.00K | 74.00K | 4.00K |
| Net Income | -59.69M | -57.13M | -42.63M | -49.97M | -55.23M | -23.19M | -8.09M |
| Net Income Ratio | -5,968.50% | -1,142.68% | -284.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| EPS Diluted | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| Weighted Avg Shares Out | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
| Weighted Avg Shares Out (Dil) | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at...
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
E tripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p < 0.0001) compared to placebo Results also showed statistically significant rapid and sustained...
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times...
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C. , Oct. 6, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the "Options") to purchase...
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023.
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 5, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the...
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
NDA submission for etripamil in patients with PSVT expected in October 2023 Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with AFib-RVR Enrollment complete in Phase 2 ReVeRA study of...
Milestone Pharmaceuticals: Worthy Of A Dart Throw
Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel delivery system and should have an NDA submitted around it next quarter.
Humble Games Showcase Reveals Dead Mage’s Wizard of Legend 2 and Bossa Studios’ Lost Skies in Debut Public Live Streamed Event
SAN FRANCISCO--(BUSINESS WIRE)--Today, Humble Games, the publishing team of the beloved Humble Bundle brand, debuted the Humble Games Showcase to a public audience, sharing insight into their slate for 2023 and beyond. During the showcase, the team doubled down on...
SAR Technology Inc. Contracts MECS for Spent E-grade Acid Regeneration Plant
ST. LOUIS--(BUSINESS WIRE)--SAR Technology Inc. (SAR Inc.), located in Tainan, Taiwan, has contracted with MECS, Inc. (MECS), a subsidiary of Elessent Clean Technologies (Elessent), for the supply of MECS® proprietary technology and equipment in support of a new spent acid...
Source: https://incomestatements.info
Category: Stock Reports